Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL) - Hamlin, P A; Rodriguez, M A; Noy, A (ASH Annual Meeting Blood, 2010)
et al.